دورية أكاديمية
Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
| العنوان: | Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD. |
|---|---|
| المؤلفون: | Jarius S; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de., Ringelstein M; Department of Neurology, Heinrich Heine University, Düsseldorf, Germany., Schanda K; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Ruprecht K; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Korporal-Kuhnke M; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany., Viehöver A; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany., Hümmert MW; Department of Neurology, Hannover Medical School, Hanover, Germany., Schindler P; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Endmayr V; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria., Gastaldi M; Neuroimmunology Laboratory and Neuroimmunology Research Unit, IRCCS Mondino Foundation National Neurological Institute, Pavia, Italy., Trebst C; Department of Neurology, Hannover Medical School, Hanover, Germany., Franciotta D; Neuroimmunology Laboratory and Neuroimmunology Research Unit, IRCCS Mondino Foundation National Neurological Institute, Pavia, Italy., Aktas O; Department of Neurology, Heinrich Heine University, Düsseldorf, Germany., Höftberger R; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria., Haas J; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany., Komorowski L; Institute of Experimental Neuroimmunology, affiliated to Euroimmun AG, Lübeck, Germany., Paul F; Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Reindl M; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Wildemann B; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. brigitte.wildemann@med.uni-heidelberg.de. |
| المصدر: | Journal of neurology [J Neurol] 2024 Jul; Vol. 271 (7), pp. 4660-4671. Date of Electronic Publication: 2024 Apr 13. |
| نوع المنشور: | Journal Article; Letter |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin ; New York, Springer-Verlag |
| مواضيع طبية MeSH: | Myelin-Oligodendrocyte Glycoprotein*/immunology , Immunoglobulin G*/blood , Immunoglobulin G*/immunology , Autoantibodies*/blood, Humans ; Female ; Male ; Adult ; Middle Aged ; Sensitivity and Specificity ; Young Adult ; Aged ; Encephalomyelitis/diagnosis ; Encephalomyelitis/immunology ; Encephalomyelitis/blood |
| مستخلص: | Background: Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD) is the most important differential diagnosis of both multiple sclerosis and neuromyelitis optica spectrum disorders. A recent proposal for new diagnostic criteria for MOG-EM/MOGAD explicitly recommends the use of immunoglobulin G subclass 1 (IgG1)- or IgG crystallizable fragment (Fc) region-specific assays and allows the use of heavy-and-light-chain-(H+L) specific assays for detecting MOG-IgG. By contrast, the utility of MOG-IgG3-specific testing has not been systematically evaluated. Objective: To assess whether the use of MOG-IgG3-specific testing can improve the sensitivity of MOG-IgG testing. Methods: Re-testing of 22 patients with a definite diagnosis of MOG-EM/MOGAD and clearly positive MOG-IgG status initially but negative or equivocal results in H+L- or Fc-specific routine assays later in the disease course (i.e. patients with spontaneous or treatment-driven seroreversion). Results: In accordance with previous studies that had used MOG-IgG1-specific assays, IgG subclass-specific testing yielded a higher sensitivity than testing by non-subclass-specific assays. Using subclass-specific secondary antibodies, 26/27 supposedly seroreverted samples were still clearly positive for MOG-IgG, with MOG-IgG1 being the most frequently detected subclass (25/27 [93%] samples). However, also MOG-IgG3 was detected in 14/27 (52%) samples (from 12/22 [55%] patients). Most strikingly, MOG-IgG3 was the predominant subclass in 8/27 (30%) samples (from 7/22 [32%] patients), with no unequivocal MOG-IgG1 signal in 2 and only a very weak concomitant MOG-IgG1 signal in the other six samples. By contrast, no significant MOG-IgG3 reactivity was seen in 60 control samples (from 42 healthy individuals and 18 patients with MS). Of note, MOG-IgG3 was also detected in the only patient in our cohort previously diagnosed with MOG-IgA + /IgG - MOG-EM/MOGAD, a recently described new disease subvariant. MOG-IgA and MOG-IgM were negative in all other patients tested. Conclusions: In some patients with MOG-EM/MOGAD, MOG-IgG is either exclusively or predominantly MOG-IgG3. Thus, the use of IgG1-specific assays might only partly overcome the current limitations of MOG-IgG testing and-just like H+L- and Fcγ-specific testing-might overlook some genuinely seropositive patients. This would have potentially significant consequences for the management of patients with MOG-EM/MOGAD. Given that IgG3 chiefly detects proteins and is a strong activator of complement and other effector mechanisms, MOG-IgG3 may be involved in the immunopathogenesis of MOG-EM/MOGAD. Studies on the frequency and dynamics as well as the clinical and therapeutic significance of MOG-IgG3 seropositivity are warranted. (© 2024. The Author(s).) |
| References: | J Neurol. 2023 Jul;270(7):3341-3368. (PMID: 37022481) Lancet Neurol. 2023 Mar;22(3):268-282. (PMID: 36706773) Ther Apher Dial. 2015 Aug;19(4):361-6. (PMID: 26386225) Arch Neurol. 2005 Nov;62(11):1673-80. (PMID: 16286539) J Neuroimmunol. 1981 Mar;1(1):125-35. (PMID: 6799544) J Neuroinflammation. 2018 May 3;15(1):134. (PMID: 29724224) J Neurol Sci. 2010 Apr 15;291(1-2):52-6. (PMID: 20117794) J Neuroinflammation. 2016 Sep 27;13(1):280. (PMID: 27793206) Front Immunol. 2020 May 06;11:740. (PMID: 32435243) J Neurol Sci. 2019 Dec 15;407:116396. (PMID: 31726278) Nervenarzt. 2018 Dec;89(12):1388-1399. (PMID: 30264269) Clin Chem Lab Med. 2010 May;48(5):659-63. (PMID: 20184532) Adv Immunol. 2014;121:213-42. (PMID: 24388217) Antibodies (Basel). 2019 Apr 25;8(2):. (PMID: 31544836) Nat Rev Dis Primers. 2020 Oct 22;6(1):85. (PMID: 33093467) Front Immunol. 2014 Oct 20;5:520. (PMID: 25368619) Neurology. 2015 Jul 14;85(2):177-89. (PMID: 26092914) Sci Transl Med. 2017 Nov 1;9(414):. (PMID: 29093180) Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89. (PMID: 25821844) J Neuroinflammation. 2017 Oct 25;14(1):208. (PMID: 29070051) Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):. (PMID: 32024795) J Neuroinflammation. 2018 Mar 19;15(1):88. (PMID: 29554927) Trends Immunol. 2019 Mar;40(3):197-211. (PMID: 30745265) Autoimmunity. 2016 Nov;49(7):472-479. (PMID: 27684107) Brain Pathol. 2013 Nov;23(6):661-83. (PMID: 24118483) J Neurol. 2017 Dec;264(12):2420-2430. (PMID: 29063242) J Neuroinflammation. 2016 Sep 26;13(1):279. (PMID: 27788675) Medicine (Baltimore). 2015 Jan;94(2):e387. (PMID: 25590841) Neurol Neuroimmunol Neuroinflamm. 2019 Aug 16;6(5):. (PMID: 31454780) J Neurol. 2020 Dec;267(12):3555-3564. (PMID: 32623596) JAMA Neurol. 2023 Sep 1;80(9):989-995. (PMID: 37548987) Ann Neurol. 2018 Aug;84(2):315-328. (PMID: 30014603) |
| فهرسة مساهمة: | Keywords: Antibodies; Aquaporin-4 (AQP4); Assays; Autoantibody; Detection antibodies; IgG subclasses; Immunoglobulin G (IgG); MOG antibody-associated disease (MOGAD); MOG antibody-associated encephalomyelitis (MOG-EM); MOG-IgG1; MOG-IgG3; Multiple sclerosis; Myelin oligodendrocyte glycoprotein (MOG); Myelitis; Neuromyelitis optica spectrum disorders (NMOSD); Optic neuritis; Rozanolixizumab; Sensitivity; Seroconversion; Serology; Seronegative; Seronegativity; Seroreversion; Tests |
| المشرفين على المادة: | 0 (Myelin-Oligodendrocyte Glycoprotein) 0 (Immunoglobulin G) 0 (Autoantibodies) 0 (MOG protein, human) |
| تواريخ الأحداث: | Date Created: 20240412 Date Completed: 20240709 Latest Revision: 20240712 |
| رمز التحديث: | 20240712 |
| مُعرف محوري في PubMed: | PMC11233316 |
| DOI: | 10.1007/s00415-024-12285-5 |
| PMID: | 38609667 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-1459 |
|---|---|
| DOI: | 10.1007/s00415-024-12285-5 |